Project Grant R01AI187192
Award Date
11/22/24
Completion Date
10/31/29
Dollars Obligated
$636K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Galveston, TX 77555, USA
Similar Awards
This $583,047 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand how Rift Valley Fever Virus (RVFV) disseminates from the site of infection in the skin to the central nervous system (CNS). The project aims to establish the routes and mechanisms by which RVFV invades the CNS following peripheral exposure, using novel rodent CNS infection models...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, provides $128,052 to Virginia Polytechnic Institute & State University (Virginia Tech) to investigate the role of the Rift Valley Fever Virus (RVFV) NSS protein in modulating the host autophagy pathway. The research aims to define the molecular mechanism of the NSS-LC3 interaction and its impact on RVFV pathogenesis in a...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $626,423 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Texas Medical Branch at Galveston (UTMB). The funding will support research to explore the dependence of arenaviruses on the metabolism of the monosaccharides D-glucose and D-mannose, with the goal of developing carbohydrate antimetabolite compounds as potential pan-arenavirus therapeutics. Specifically,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $92,809,964 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Texas Medical Branch at Galveston (UTMB) on July 30, 2024. The PARAMYXOVIRIDAE AND BUNYAVIRALES VACCINES AND ANTIBODIES CENTER (PABVAX) project will focus on developing, testing, and translating prototype subunit vaccines using a novel microneedle patch platform, as well as developing new...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $242,185 to Texas A&M AgriLife Research to investigate the role of RNA structure in the regulation of developmental RNA editing in the parasitic kinetoplastids, including Trypanosoma brucei. The research aims to determine how RNA conformation and ribonucleoprotein complexes impact the early checkpoints of the RNA...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $798,400 in funding to the University of Texas Medical Branch at Galveston to investigate a novel circular RNA vaccine platform for the Andes virus, a hantavirus that causes Hantavirus Cardiopulmonary Syndrome. The project aims to evaluate the ability of the circular RNA vaccine to induce a more potent and durable...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $624,902 to The University of Texas Health Science Center at San Antonio to investigate the role of the HIV accessory protein Vpr in facilitating viral persistence in myeloid cells. The research aims to characterize how Vpr induces epigenetic remodeling at HIV integration sites, which may reveal novel therapeutic...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $453,429 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Texas A&M AgriLife Research to investigate the regulation of RNA editing in two life cycle stages of Trypanosoma brucei, a pathogenic kinetoplastid protozoa. The research aims to provide insights into the key proteins and mechanisms involved in differential RNA editing across the T. brucei life cycle, which alternates between mammalian...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, provides $463,698 to the University of Texas Medical Branch at Galveston (UTMB) to conduct pre-clinical studies on repurposing FDA-approved adenosine A2A receptor antagonists for treating lethal rickettsial infections. The goal is to determine the role of A2A receptor signaling in rickettsial infections and identify lead...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $440,000.00 in funding to the University of Texas Medical Branch at Galveston (UTMB) to conduct research on two key areas: Characterizing the mechanisms by which contractile injection systems, such as phage tails and tailocins, breach bacterial cell envelopes. This knowledge will inform the design and retargeting of R-type...